Kyowa Kirin Co., Ltd. (TYO:4151)
2,336.50
+38.00 (1.65%)
Oct 1, 2025, 3:30 PM JST
Kyowa Kirin Employees
Kyowa Kirin had 5,669 employees as of December 31, 2024. The number of employees decreased by 305 or -5.11% compared to the previous year.
Employees
5,669
Change (1Y)
-305
Growth (1Y)
-5.11%
Revenue / Employee
87.01M JPY
Profits / Employee
6.78M JPY
Market Cap
1,203.24B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5,669 | -305 | -5.11% |
Dec 31, 2023 | 5,974 | 222 | 3.86% |
Dec 31, 2021 | 5,752 | 329 | 6.07% |
Dec 31, 2020 | 5,423 | 156 | 2.96% |
Dec 31, 2019 | 5,267 | -1,975 | -27.27% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Chugai Pharmaceutical | 5,026 |
HOYA Corporation | 37,909 |
Takeda Pharmaceutical Company | 47,455 |
Daiichi Sankyo Company | 19,765 |
Otsuka Holdings | 35,338 |
Astellas Pharma | 13,643 |
Shionogi & | 4,955 |
Olympus | 29,297 |
Kyowa Kirin News
- 21 days ago - Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis - Benzinga
- 21 days ago - Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab - GuruFocus
- 21 days ago - Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug - Seeking Alpha
- 22 days ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab ... - GuruFocus
- 22 days ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 ASCEND ... - GuruFocus
- 6 weeks ago - Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers - GlobeNewsWire
- 2 months ago - Kyowa Kirin Co., Ltd. (KYKOF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress - PRNewsWire